BR112022012362A2 - Anticorpos cd163 ou proteínas de ligação - Google Patents

Anticorpos cd163 ou proteínas de ligação

Info

Publication number
BR112022012362A2
BR112022012362A2 BR112022012362A BR112022012362A BR112022012362A2 BR 112022012362 A2 BR112022012362 A2 BR 112022012362A2 BR 112022012362 A BR112022012362 A BR 112022012362A BR 112022012362 A BR112022012362 A BR 112022012362A BR 112022012362 A2 BR112022012362 A2 BR 112022012362A2
Authority
BR
Brazil
Prior art keywords
porcine
antibodies
antigen
binds
amino acid
Prior art date
Application number
BR112022012362A
Other languages
English (en)
Portuguese (pt)
Inventor
Owen Charles
Abdelaali Benchaoui Hafid
TAIT-BURKARD Christine
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Publication of BR112022012362A2 publication Critical patent/BR112022012362A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022012362A 2019-12-24 2020-12-24 Anticorpos cd163 ou proteínas de ligação BR112022012362A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (1)

Publication Number Publication Date
BR112022012362A2 true BR112022012362A2 (pt) 2022-09-06

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012362A BR112022012362A2 (pt) 2019-12-24 2020-12-24 Anticorpos cd163 ou proteínas de ligação

Country Status (13)

Country Link
US (1) US20230203185A1 (https=)
EP (1) EP4081542A1 (https=)
JP (1) JP7702952B2 (https=)
KR (1) KR20220119147A (https=)
CN (1) CN121873247A (https=)
BR (1) BR112022012362A2 (https=)
CL (1) CL2022001706A1 (https=)
CO (1) CO2022010294A2 (https=)
DO (2) DOP2022000136A (https=)
GB (1) GB201919294D0 (https=)
MX (1) MX2022007957A (https=)
PE (1) PE20230384A1 (https=)
WO (1) WO2021130502A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
WO2024156888A1 (en) * 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3331355T3 (fi) * 2015-08-06 2024-06-17 Univ Missouri Sikojen lisääntymishäiriö- ja keuhkotulehdusoireyhtymävirukselle (PRRSV) resistentti sika ja soluja, joilla on muokattuja CD163-geenejä
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
US20230203185A1 (en) 2023-06-29
JP2023508674A (ja) 2023-03-03
CA3162664A1 (en) 2021-07-01
JP7702952B2 (ja) 2025-07-04
PE20230384A1 (es) 2023-03-06
EP4081542A1 (en) 2022-11-02
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
CL2022001706A1 (es) 2023-05-26
KR20220119147A (ko) 2022-08-26
GB201919294D0 (en) 2020-02-05
CO2022010294A2 (es) 2022-10-31
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CN121873247A (zh) 2026-04-17
CN115151569A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
BR112022012362A2 (pt) Anticorpos cd163 ou proteínas de ligação
BR112021016955A2 (pt) Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
BRPI0610796B8 (pt) anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
CL2023001888A1 (es) Anticuerpos multiespecíficos con especificidad para il-4r e il-31.
EA202090247A1 (ru) Антитела против cd166 и их применения
BR112021024553A2 (pt) Molécula de ligação específica para cd73 e uso de molécula de ligação
BR112023000826A2 (pt) Anticorpo anti-ctla-4 e uso do mesmo
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
BRPI0509847B8 (pt) anticorpo que se liga à p-seletina, seu método de preparo e uso, vetor, composição e kit
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112021022171A2 (pt) Anticorpo para tigit, seu uso e método para produzir o mesmo
BR112022024084A2 (pt) Receptores de antígeno quiméricos específicos para p95her2 e usos dos mesmos
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
BRPI0414515A (pt) moléculas de ligação terapêuticas
MX2021013441A (es) Molecula de union a antigenos, composicion farmaceutica y metodo.
JP2019504014A5 (https=)
BR112022004603A2 (pt) Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
BR112022001017A2 (pt) Anticorpo monoclonal anti-vegf humanizado
BR112014002929A8 (pt) Novos anticorpos contra fosforilcolina
BR112022021893A2 (pt) Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune
BR112022011323A2 (pt) Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos
BR112022024161A2 (pt) Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica
BR112022002376A2 (pt) Anticorpos que se ligam especificamente à troponina t cardíaca humana, anticorpos, moléculas de ácido nucleico, vetor, composição e método para determinar a troponina t cardíaca humana
AR130641A1 (es) Anticuerpos anti-cd28

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ECO ANIMAL HEALTH LTD. (GB)